Do analysts rate PMCB or EVAX?

Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 229.34%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts plainly believe Evaxion A/S is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is PMCB or EVAX more profitable?

Nuvilex's return on equity of 0.25% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 0.25% 0.18% Evaxion A/S N/A -73.56% -37.45%

Do analysts recommend PMCB or ATNM?

Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 380.77%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is PMCB or ATNM more profitable?

Nuvilex's return on equity of 0.25% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 0.25% 0.18% Actinium Pharmaceuticals N/A -100.85% -47.89%

Do analysts rate PMCB or BRNS?

Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 576.82%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PMCB or BRNS more profitable?

Nuvilex's return on equity of 0.25% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 0.25% 0.18% Barinthus Biotherapeutics N/A -59.15% -43.80%

Do analysts rate PMCB or LGVN?

Longeveron has a consensus price target of $8.00, indicating a potential upside of 981.23%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PMCB or LGVN more profitable?

Nuvilex has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Nuvilex's return on equity of 0.25% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 0.25% 0.18% Longeveron -1,977.59% -223.19% -150.20%

Do analysts rate MDXH or PMCB?

MDxHealth currently has a consensus price target of $2.83, indicating a potential upside of 250.66%. Given MDxHealth's stronger consensus rating and higher possible upside, equities analysts clearly believe MDxHealth is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MDXH or PMCB more profitable?

Nuvilex has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Nuvilex's return on equity of 0.25% beat MDxHealth's return on equity. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -23.38% Nuvilex N/A 0.25% 0.18%

Nuvilex (PMCB) Competitors

$0.55 +0.00 (+0.18%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$0.55 0.00 (0.00%)

As of 08/14/2026 07:57 PM Eastern

Compare

PMCB vs. EVAX, ATNM, BRNS, LGVN, and MDXH

Should you buy Nuvilex stock or one of its competitors? Nuvilex's main competitors and comparable companies include Evaxion A/S (EVAX), Actinium Pharmaceuticals (ATNM), Barinthus Biotherapeutics (BRNS), Longeveron (LGVN), and MDxHealth (MDXH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvilex compare to Evaxion A/S?

Nuvilex (NASDAQ:PMCB) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Nuvilex's return on equity of 0.25% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	0.25%	0.18%
Evaxion A/S	N/A	-73.56%	-37.45%

Evaxion A/S has higher revenue and earnings than Nuvilex. Evaxion A/S is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A
Evaxion A/S	$7.53M	3.70	-$7.71M	-$1.47	N/A

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 11.0% of Nuvilex shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 229.34%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts plainly believe Evaxion A/S is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Nuvilex has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

In the previous week, Evaxion A/S had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Evaxion A/S and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.89 beat Evaxion A/S's score of 0.93 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Evaxion A/S	Positive

Summary

Evaxion A/S beats Nuvilex on 8 of the 14 factors compared between the two stocks.

How does Nuvilex compare to Actinium Pharmaceuticals?

Nuvilex (NASDAQ:PMCB) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Nuvilex has higher earnings, but lower revenue than Actinium Pharmaceuticals. Nuvilex is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A
Actinium Pharmaceuticals	$35.09M	0.93	-$48.82M	$0.36	2.89

In the previous week, Actinium Pharmaceuticals had 7 more articles in the media than Nuvilex. MarketBeat recorded 8 mentions for Actinium Pharmaceuticals and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.89 beat Actinium Pharmaceuticals' score of -0.40 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Actinium Pharmaceuticals	Neutral

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nuvilex has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Nuvilex's return on equity of 0.25% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	0.25%	0.18%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 380.77%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Nuvilex beats Actinium Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Nuvilex compare to Barinthus Biotherapeutics?

Nuvilex (NASDAQ:PMCB) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 576.82%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.89 beat Barinthus Biotherapeutics' score of 0.44 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Barinthus Biotherapeutics	Neutral

Nuvilex's return on equity of 0.25% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	0.25%	0.18%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

Nuvilex has higher earnings, but lower revenue than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A
Barinthus Biotherapeutics	$14.97M	1.61	-$66.43M	-$1.03	N/A

Nuvilex has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 11.0% of Nuvilex shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Nuvilex beats Barinthus Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Nuvilex compare to Longeveron?

Nuvilex (NASDAQ:PMCB) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Longeveron has a consensus price target of $8.00, indicating a potential upside of 981.23%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nuvilex has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market.

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Longeveron had 6 more articles in the media than Nuvilex. MarketBeat recorded 7 mentions for Longeveron and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.89 beat Longeveron's score of 0.00 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Longeveron	Neutral

Nuvilex has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Nuvilex's return on equity of 0.25% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	0.25%	0.18%
Longeveron	-1,977.59%	-223.19%	-150.20%

Nuvilex has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A
Longeveron	$1.20M	19.21	-$22.70M	-$0.99	N/A

Summary

Nuvilex beats Longeveron on 9 of the 15 factors compared between the two stocks.

How does Nuvilex compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Nuvilex has lower revenue, but higher earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.72	N/A
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A

In the previous week, MDxHealth had 12 more articles in the media than Nuvilex. MarketBeat recorded 13 mentions for MDxHealth and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.89 beat MDxHealth's score of 0.53 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
MDxHealth	Positive
Nuvilex	Very Positive

MDxHealth currently has a consensus price target of $2.83, indicating a potential upside of 250.66%. Given MDxHealth's stronger consensus rating and higher possible upside, equities analysts clearly believe MDxHealth is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Nuvilex's return on equity of 0.25% beat MDxHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-23.38%
Nuvilex	N/A	0.25%	0.18%

MDxHealth has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

34.2% of Nuvilex shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 11.0% of Nuvilex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Nuvilex beats MDxHealth on 8 of the 15 factors compared between the two stocks.

Get Nuvilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMCB vs. The Competition

Export

Metric	Nuvilex	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.92M	$3.72B	$7.03B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.64%
P/E Ratio	-0.18	10.83	271.54	25.40
Price / Sales	N/A	1,360.21	673.88	125.76
Price / Cash	N/A	101.42	75.70	53.27
Price / Book	0.18	16.78	12.92	6.21
Net Income	-$19.42M	-$13.32M	$3.45B	$347.71M
7 Day Performance	-6.63%	1.76%	1.16%	1.08%
1 Month Performance	-16.49%	2.86%	2.17%	1.87%
1 Year Performance	-37.88%	54.10%	62.38%	20.79%

Nuvilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMCB Nuvilex	1.4323 of 5 stars	$0.55 +0.2%	N/A	-37.9%	$5.92M	N/A	N/A	4	Positive News
EVAX Evaxion A/S	3.411 of 5 stars	$2.99 +0.3%	$11.00 +267.9%	+16.0%	$24.85M	$7.53M	N/A	60	News Coverage Gap Up
ATNM Actinium Pharmaceuticals	1.9663 of 5 stars	$0.79 +5.1%	$5.00 +535.3%	-38.5%	$24.69M	$90K	N/A	30	News Coverage Analyst Revision
BRNS Barinthus Biotherapeutics	2.3063 of 5 stars	$0.58 +1.2%	$4.00 +593.2%	-52.9%	$23.29M	$14.97M	N/A	107	Positive News Analyst Downgrade Short Interest Increase High Trading Volume
LGVN Longeveron	1.4443 of 5 stars	$0.77 +6.4%	$5.50 +611.1%	-2.6%	$22.65M	$1.20M	N/A	20	News Coverage Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMCB) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvilex (PMCB) Competitors